Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes JACC Guideline Comparison

被引：80

作者：

Kelsey, Michelle D. ^{[1
,2
]}

Nelson, Adam J. ^{[2
]}

Green, Jennifer B. ^{[2
,3
]}

Granger, Christopher B. ^{[1
,2
]}

Peterson, Eric D. ^{[4
,5
]}

McGuire, Darren K. ^{[4
,5
]}

Pagidipati, Neha J. ^{[1
,2
]}

机构：

[1] Duke Univ, Dept Med, Div Cardiol, Med Ctr, Durham, NC 27701 USA

[2] Duke Clin Res Inst, Durham, NC USA

[3] Duke Univ, Dept Med, Div Endocrinol, Med Ctr, Durham, NC 27701 USA

[4] Univ Texas Southwestern Med Ctr Dallas, Div Cardiol, Dept Med, Dallas, TX 75390 USA

[5] Parkland Hlth & Hosp Syst, Dallas, TX 75390 USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2022年 / 79卷 / 18期

关键词：

guidelines; prevention; type 2 diabetes mellitus; COMMUNITY-PREVENTIVE-SERVICES; BLOOD-PRESSURE; AMERICAN-COLLEGE; TASK-FORCE; RENAL OUTCOMES; DISEASE; ASSOCIATION; MANAGEMENT; ADULTS; ENDOCRINOLOGY;

D O I：

10.1016/j.jacc.2022.02.046

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cardiovascular disease is a leading cause of morbidity and mortality in individuals with type 2 diabetes mellitus. These high-risk patients benefit from aggressive risk factor management, with blood pressure and low-density lipoprotein-cholesterol treatment, glycemic control, kidney protection, and lifestyle intervention. There are several recommendation and guideline documents across cardiology, endocrinology, nephrology, and general medicine professional societies from the United States and Europe with recommendations for cardiovascular risk reduction in patients with type 2 diabetes mellitus. Although there are some noteworthy differences, particularly in risk stratification, low-density lipoprotein-cholesterol and blood pressure treatment targets, and the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists, overall there is considerable alignment across recommendations from different professional societies. (C) 2022 by the American College of Cardiology Foundation.

引用

页码：1849 / 1857

页数：9

共 47 条

[1] 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022 [J].

American Diabetes Association Professional Practice Committee .

DIABETES CARE, 2022, 45 :S144-S174

[2] 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022 [J].

American Diabetes Association Professional Practice Committee .

DIABETES CARE, 2022, 45 :S125-S143

[3]

American Diabetes Association Professional Practice Committee, 2021, DIABETES CARE, V45, pS175

[4] KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease Abstracts [J].

不详 .

KIDNEY INTERNATIONAL, 2021, 99 (03) :S26-S87

[5]

[Anonymous], International, DOI DOI 10.2337/dc10-S011

[6]

[Anonymous], 2017, ENDOCR PRACT, V23, P1

[7]

Arnett DK, 2019, CIRCULATION, V140, pE596, DOI [10.1161/CIR.0000000000000678, 10.1161/CIR.0000000000000677, 10.1016/j.jacc.2019.03.009, 10.1016/j.jacc.2019.03.010]

[8] Combined Diet and Physical Activity Promotion Programs to Prevent Type 2 Diabetes Among Persons at Increased Risk: A Systematic Review for the Community Preventive Services Task Force [J].

Balk, Ethan M. ;

Earley, Amy ;

Raman, Gowri ;

Avendano, Esther A. ;

Pittas, Anastassios G. ;

Remington, Patrick L. .

ANNALS OF INTERNAL MEDICINE, 2015, 163 (06) :437-+

[9] Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose Observations From Traditional and Bayesian Random-Effects Meta-Analyses of Randomized Trials [J].

Bangalore, Sripal ;

Kumar, Sunil ;

Lobach, Iryna ;

Messerli, Franz H. .

CIRCULATION, 2011, 123 (24) :2799-+

[10] Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials [J].

Basu, Sanjay ;

Sussman, Jeremy B. ;

Rigdon, Joseph ;

Steimle, Lauren ;

Denton, Brian T. ;

Hayward, Rodney A. .

PLOS MEDICINE, 2017, 14 (10)

← 1 2 3 4 5 →